Generali Asset Management SPA SGR Has $1.79 Million Stock Holdings in United Therapeutics Corporation $UTHR

Key Points

• Generali Asset Management SPA SGR lowered its stake in United Therapeutics Corporation by 19.3%, holding 6,215 shares worth approximately $1.79 million.
• Several institutional investors, including Chung Wu Investment Group LLC and SVB Wealth LLC, acquired new stakes in United Therapeutics recently, highlighting growing interest in the company.
• United Therapeutics reported missed earnings estimates for the last quarter, posting an EPS of $6.41 against a consensus expectation of $6.80, despite a revenue increase of 11.7% year-over-year.

Generali Asset Management SPA SGR decreased its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 19.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,215 shares of the biotechnology company's stock after selling 1,486 shares during the period. Generali Asset Management SPA SGR's holdings in United Therapeutics were worth $1,786,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at about $29,000. SVB Wealth LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at about $32,000. Geneos Wealth Management Inc. increased its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares during the period. Brooklyn Investment Group increased its stake in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after buying an additional 98 shares during the period. Finally, WPG Advisers LLC bought a new stake in shares of United Therapeutics during the 1st quarter valued at about $60,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $440.35, for a total value of $9,907,875.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of the firm's stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $431.31, for a total value of $1,725,240.00. Following the completion of the transaction, the chief executive officer owned 130 shares in the company, valued at $56,070.30. This represents a 96.85% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 292,435 shares of company stock valued at $118,956,307. Company insiders own 10.30% of the company's stock.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $433.34 on Friday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48. The stock has a 50 day moving average price of $385.69 and a two-hundred day moving average price of $327.93. The stock has a market capitalization of $19.55 billion, a PE ratio of 16.91, a price-to-earnings-growth ratio of 4.72 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period last year, the business posted $5.85 EPS. The company's revenue was up 11.7% on a year-over-year basis. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on UTHR shares. Bank of America upped their target price on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research report on Tuesday, September 2nd. Wells Fargo & Company upped their target price on United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Royal Bank Of Canada started coverage on United Therapeutics in a research report on Friday, September 26th. They set an "outperform" rating and a $569.00 target price on the stock. HC Wainwright upped their target price on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a research report on Friday, September 5th. Finally, Morgan Stanley upped their target price on United Therapeutics from $328.00 to $435.00 and gave the company an "equal weight" rating in a research report on Friday, October 10th. Ten equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $457.21.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.